Management of Patients Treated With Immunotherapy
Immunotherapy, one of the most important breakthroughs for cancer treatment in the past decade, is demonstrating its effectiveness across tumor types, including non–small cell lung cancer. This activity will provide information on the newest agents in the armamentarium for treating non–small cell lung cancer, including PD-1 inhibitor, and anti-CTLA4 immunotherapy. In addition, the discussion will include the recognition and management of potential immune-mediated adverse events unique to immune checkpoint inhibitors.
Credits/Contact Hours: 0.25
You can no longer earn CE credit for this program, however, please participate in the education here:
Participate Without Claiming Credit
* This link will take you to the
Meniscus Educational Institute website.